Valink Therapeutics focuses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications
Valink Therapeutics focuses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications.